Description
CJC-1295 + Ipamorelin combines two complementary research peptides: CJC-1295 (No DAC), a growth hormone-releasing hormone (GHRH) analog, and Ipamorelin, a selective ghrelin receptor agonist. This combination is studied for its complementary activity involving growth hormone release, pituitary signaling, and targeted receptor activation. The dual-peptide formulation provides a useful research model for examining how different signaling pathways may work together to influence growth hormone secretion.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Not for human consumption.
Reviews
There are no reviews yet.